세계의 펩타이드 암 백신 시장 규모 : 유형별, 기술별, 용도별, 지역 범위별 예측

Peptide Cancer Vaccine Market Size And Forecast

Peptide Cancer Vaccine Market size was valued at USD 890.85 Million in 2024 and is projected to reach USD 3337.04 Million by 2032, growing at a CAGR of 19.80% during the forecast period 2026-2032.

The Global Peptide Cancer Vaccine Market has witnessed strong growth owing to a rise in the number of cancer patients, technological advancements, new cancer drug advances, increasing government aid, the expanding older population, and the peptide cancer vaccine's long-term impact and selectivity. Almost one-third of cancer deaths are caused by tobacco use, a high BMI, alcohol use, a low fruit and vegetable intake, and a lack of physical exercise. As a result, there is a high need for cancer vaccines to prevent and cure cancer, moving the market for peptide cancer vaccines ahead. The Global Peptide Cancer Vaccine Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Peptide Cancer Vaccine Market Drivers

The market drivers for the Peptide Cancer Vaccine Market can be influenced by various factors. These may include:

Growing Cancer Incidence: As cancer rates continue to rise worldwide, there is an increasing need for cancer treatments that work, such as vaccinations.

Developments in Immunotherapy: With its promise to provide individualised and targeted treatment choices, immunotherapy, including cancer vaccines, has received a lot of interest in recent years.

Increasing Interest in Precision Medicine: Peptide cancer vaccines are a component of the larger movement in precision medicine, which attempts to customise care for each patient according to their genetic composition and unique cancer traits.

Technological developments: Peptide synthesis, vaccine delivery methods, and bioinformatics have all advanced, improving the efficacy and development of peptide cancer vaccines and raising their prospects as a therapeutic option.

funding in Research and Development: The creation and commercialization of peptide-based vaccinations have been expedited by increased public and private sector funding in the study and development of cancer vaccines.

Positive Regulatory Environment: As a result of regulatory bodies' growing recognition of the promise of cancer vaccines and their streamlining of the licencing procedures for these cutting-edge therapies, the market is poised to expand.

Growing Healthcare Expenditure: As healthcare costs rise globally, people and healthcare professionals are becoming more open to investigating cutting-edge therapy options such peptide cancer vaccines.

Partnerships and Collaborations: Research centres, biotechnology companies, and pharmaceutical corporations are working together to promote innovation and hasten the creation and broader distribution of peptide cancer vaccines.

Growing Awareness and Acceptance: Peptide cancer vaccines are becoming more widely accepted as a result of increased patient and healthcare professional knowledge about cancer vaccines as well as a move towards proactive healthcare management.

Possibility for Combination Therapies: Peptide cancer vaccines can be more effective and have a larger market potential when used in conjunction with other cancer treatments such radiation therapy, chemotherapy, and checkpoint inhibitors.

Global Peptide Cancer Vaccine Market Restraints

Several factors can act as restraints or challenges for the Peptide Cancer Vaccine Market. These may include:

High Development Costs: Peptide cancer vaccines have high research and development costs, including expenses for clinical trials, production, and regulatory approval procedures. These expensive prices may discourage investment and impede the advancement of vaccine technology.

Complexity of Vaccine Design: A thorough understanding of tumour antigens and immune responses is necessary to design successful peptide cancer vaccines. The process of developing vaccines that are customised for each patient can be slowed significantly by the difficulties involved in selecting appropriate antigens.

Regulatory Obstacles: The approval procedures for new vaccinations under regulation can be difficult and time-consuming. To prove safety, efficacy, and manufacturing consistency, peptide cancer vaccines must go through extensive testing, which may cause a delay in their release onto the market.

Limited Efficacy: Peptide cancer vaccines show promise as a customised therapeutic approach, but patient-to-patient variability exists in their ability to mount a strong and long-lasting immune response against cancer cells. It is still difficult to achieve consistent efficacy across many cancer types and patient demographics.

Competition from Other Therapies: Immune checkpoint inhibitors, radiation therapy, chemotherapy, and targeted therapies are some of the cancer treatment methods that peptide cancer vaccines must contend with. It may be difficult for peptide vaccines to become widely used due to the established market positions and shown benefits of these treatments.

Accessibility and affordability: High expenses, a dearth of healthcare infrastructure, and problems with reimbursement may restrict a region's capacity to obtain peptide cancer vaccines. For the vaccine business to expand, it is imperative that vaccinations remain accessible and affordable for patients everywhere.

Safety Concerns: Adoption of peptide cancer vaccines may be impacted by safety concerns, which include possible adverse effects and autoimmune reactions. Gaining the trust of doctors and patients requires addressing safety concerns through meticulous vaccine design and clinical testing.

Intellectual Property Problems: Rights to peptide cancer vaccines may give rise to intellectual property conflicts that impede cooperation and progress in the field. Promoting cooperation among stakeholders and removing obstacles related to intellectual property are crucial for expanding the market.

Global Peptide Cancer Vaccine Market: Segmentation Analysis

The Global Peptide Cancer Vaccine Market is segmented on the basis of Type, Technology, Application, And Geography.

Peptide Cancer Vaccine Market, By Type

• Personalized Peptide Vaccine
• Peptide-Pulsed Dendritic Cancer Vaccine
• Peptide Cocktail Type
• Multivalent Peptide Vaccine
• Others

Based on Type, The market is segmented into Personalized Peptide Vaccine, Peptide-Pulsed Dendritic Cancer Vaccine, Peptide Cocktail Type, Multivalent Peptide Vaccine, and Others. The Peptide-Pulsed Dendritic Cancer Vaccine segment holds the largest market share during the forecast period. With the application of the Peptide-Pulsed Dendritic Cancer Vaccine, most of the problems associated with cancer immunotherapy are expected to be resolved.

Peptide Cancer Vaccine Market, By Technology

• Recombinant Cancer Vaccines
• Whole-cell Cancer Vaccines
• Viral Vector and DNA Cancer Vaccines
• Other Technologies (Dendritic Cells, Antigen, etc.)

Based on Technology, The market is segmented into Recombinant Cancer Vaccines, Whole-cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines, and Other Technologies (Dendritic Cells, Antigen, etc.). The Recombinant Cancer Vaccines sector now leads the worldwide market and is projected to do so for the foreseeable future. This is due to the enormous number of cancer vaccinations that have been licensed utilizing recombinant technology. This comprises inserting DNA encoding an antigen into mammalian cells that activates an immune reaction, expressing the antigen in these cells, and then extracting it from them.

Peptide Cancer Vaccine Market, By Application

• Breast Cancer
• Lung Cancer
• Melanoma
• Prostate Cancer
• Others

Based on Application, The market is segmented into Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Others. The Prostate Cancer segment is estimated to witness the highest CAGR during the forecast period. The factors that can be attributed to the rise in demand for Provenge (prostate cancer vaccine) along with the increase in the number of prostate cancer vaccines in the pipeline are fueling the demand for this segment.

Peptide Cancer Vaccine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Regional Analysis, The Global Peptide Cancer Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The Peptide Cancer Vaccine Market is expected to have the most growth in North America. The presence of a significant number of biotech and pharmaceutical participants in this area is supporting the demand for the Peptide Cancer Vaccine Market. Furthermore, the increased occurrence of cancer is fueling the growth of the Peptide Cancer Vaccine Market in this area. During the projected period, Asia Pacific is expected to be the fastest-expanding region in the Peptide Cancer Vaccine Market. This increase might be attributed to the region's growing research activity. These research endeavors improve access and promote cost-effective operational efficiency.

Key Players

The "Global Peptide Cancer Vaccine Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Boston Biomedical, VAXON Biotech, TapImmune, Sellas, ISA Pharmaceuticals, Generex Biotechnology, Immatics, OncoTherapy Science, BrightPath Biotherapeutics, Enzo Life Science, OSE Immunotherapeutics, GlaxoSmithKline PLC, Moderna Inc., Merck and Co Inc., F Hoffmann-La Roche AG, Galena Biopharma, Agenus Inc., BioNTech SE, Genexine Inc., Phosplatin Therapeutics, Provectus Biopharmaceuticals, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In December 2021, in an educational session at the ESMO Immune-Oncology Congress 2021, ISA Pharmaceuticals discussed critical learnings in cancer vaccine development.
• In November 2019, new results from a phase 1 study testing DSP-7888, an experimental WT1 cancer peptide vaccine, in patients with advanced malignancies, were presented by Boston Biomedical, Inc.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PEPTIDE CANCER VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PEPTIDE CANCER VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL PEPTIDE CANCER VACCINE MARKET, BY TECHNOLOGY

• 5.1 Overview
• 5.2 Recombinant Cancer Vaccines
• 5.3 Whole-cell Cancer Vaccines
• 5.4 Viral Vector and DNA Cancer Vaccines
• 5.5 Other Technologies (Dendritic Cells, Antigen, etc.)

6 GLOBAL PEPTIDE CANCER VACCINE MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Breast Cancer
• 6.3 Lung Cancer
• 6.4 Melanoma
• 6.5 Prostate Cancer
• 6.6 Others

7 GLOBAL PEPTIDE CANCER VACCINE MARKET, BY TYPE

• 7.1 Overview
• 7.2 Personalized Peptide Vaccine
• 7.3 Peptide-Pulsed Dendritic Cancer Vaccine
• 7.4 Peptide Cocktail Type
• 7.5 Multivalent Peptide Vaccine
• 7.6 Others

8 GLOBAL PEPTIDE CANCER VACCINE MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL PEPTIDE CANCER VACCINE MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 OSE Immunotherapeutics
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 GlaxoSmithKline PLC
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Moderna Inc.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Merck and Co Inc.
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 F Hoffmann-La Roche AG
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 BrightPath Biotherapeutics
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Boston Biomedical
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 VAXON Biotech
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Generex Biotechnology
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 ISA Pharmaceuticals
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research